Home / Stocks / Sunil Healthcare Ltd.
SUNLOC

Sunil Healthcare Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹70.04

Change

-5.17 (-6.87%)

Open

₹75.0

Prev. Close

₹75.21

Day High

₹75.0

Day Low

₹70.0

Volume Analysis

Traded

130

Delivered

41

Delivery %

31.54%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Low return on equity (6.01%)
  • •Below-average fundamentals quality score (44/100)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹78.36 ₹76.68 ₹73.36 ₹71.68 ₹68.36 ₹66.68 ₹63.36
Fibonacci ₹76.68 ₹74.77 ₹73.59 ₹71.68 ₹69.77 ₹68.59 ₹66.68
Camarilla ₹71.42 ₹70.96 ₹70.5 ₹71.68 ₹69.58 ₹69.12 ₹68.67

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-2.21%

1 Month

+9.27%

3 Months

+1.51%

6 Months

—

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹90.26

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

9.23%

Net margin 3.52% × asset turnover 0.95x × equity multiplier 2.76x

Company Overview

Sector

Healthcare

Market Cap

₹78 Cr

P/E (TTM)

26.6

ROE

6.01%

Book Value

₹71.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Sunil Healthcare Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 44/100. The strongest factor is Cash Flow (75/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (6.01%); below-average fundamentals quality score (44/100).

TopFund Score — Fundamentals Quality

44/100 — Weak

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

64

Growth

0

Valuation

66

Cash Flow

75

Corporate Governance

56

Momentum

64

Institutional Ownership

30

Business Quality

40

Risk & Volatility

35

Liquidity

11

From Screener.in

  • +Stock is trading at 1.03 times its book value
  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -0.65% over past five years.
  • −Company has a low return on equity of 0.59% over last 3 years.
  • −Company has high debtors of 188 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Copy of newspaper publication of financial results for the quarter and half year ended 30.09.2026

Reg. 74(5) compliance certificate for quarter ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 24 23 21 22 20 20 21 23 24 22 20 19 19
Expenses + 22 23 19 19 18 18 18 19 20 18 18 16 17
Operating Profit 1 -1 3 2 2 3 3 3 4 4 2 3 2
OPM % 5.15% -2.78% 12.58% 10.28% 11.4% 13.2% 14.29% 14.44% 16.71% 16.58% 9.84% 15.43% 11.97%
Other Income + 0 3 1 0 0 1 0 1 0 1 0 0 1
Interest 1 1 2 2 2 2 2 1 1 2 2 2 2
Depreciation 2 1 1 1 2 2 2 2 2 2 2 1 1
Profit before tax -1 0 0 -1 -1 0 0 1 1 1 -1 0 0
Tax % -25.34% -48.72% 5.88% 6.25% 7.69% 57.14% -28.57% 11.65% 23.66% 30.95% -258.95% -130.0% 20.0%
Net Profit + -1 0 0 -1 -1 -1 0 1 1 1 2 0 0
EPS in Rs -1 0 0 -1 -1 -1 0 1 1 1 1 0 0
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -23 -10 0 -4 -15 -10 -1 5 16 7 -7 -16 -18

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 73 82 108 91 81 70 91 119 110 90 83 88 80
Expenses + 61 67 93 77 70 77 85 102 94 86 73 75 69
Operating Profit 12 15 15 14 11 -7 5 17 16 4 10 13 11
OPM % 16.62% 18.23% 13.97% 15.21% 13.92% -9.9% 5.9% 14.59% 14.63% 4.72% 12.42% 14.56% 13.53%
Other Income + 1 1 1 2 0 14 6 2 5 5 1 2 2
Interest 3 4 4 5 7 7 5 3 4 6 6 6 7
Depreciation 4 4 4 5 6 6 6 6 7 6 6 6 6
Profit before tax 6 8 8 6 -1 -6 -1 9 9 -3 -1 2 0
Tax % 35.39% 34.99% 36.25% 28.68% -20.45% -11.25% 16.36% 30.67% 29.5% -30.08% 16.53% -79.37% —
Net Profit + 4 5 5 4 -1 -5 -1 6 7 -2 -1 4 3
EPS in Rs 4 5 5 4 -1 -5 -1 6 7 -2 -1 4 3
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth 18 12 — -16 -11 -13 29 31 -7 -18 -8 5 -9

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 16 21 33 37 37 34 33 40 46 58 57 59 63
Borrowings + 25 37 45 61 55 49 50 35 37 66 69 59 66
Other Liabilities + 13 18 31 34 36 36 27 25 28 24 26 36 35
Total Liabilities 64 86 119 142 138 130 121 110 121 158 162 165 174
Fixed Assets + 27 41 60 71 69 70 70 70 70 87 94 86 83
CWIP 1 0 0 0 2 0 0 2 0 6 0 2 4
Investments 0 0 0 0 0 0 1 1 0 0 0 0 0
Other Assets + 35 45 59 71 66 60 50 37 50 66 68 77 87
Total Assets 64 86 119 142 138 130 121 110 121 158 162 165 174
Equity Capital 10 10 10 10 10 10 10 10 10 10 10 10 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 6 8 11 5 15 4 17 23 7 -15 12 22
Cash from Investing Activity + -8 -15 -13 -17 -3 -3 -11 -4 -3 -10 -8 -3
Cash from Financing Activity + 3 8 2 11 -12 -2 -6 -19 -4 25 -4 -19
Net Cash Flow 0 1 0 -1 0 0 -1 0 0 -1 0 0
Free Cash Flow -2 -7 -2 -10 9 4 10 13 4 -26 3 19
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 75 65 82 50 134 -64 315 136 55 -344 111 175

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 73.53% → 73.53%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 26.37% 26.35% 26.37% 26.36% 26.37% 26.36% 26.38% 26.37% 26.36% 26.37% 26.37% 26.37%
Promoters 73.53% 73.53% 73.53% 73.53% 73.53% 73.53% 73.53% 73.53% 73.53% 73.53% 73.53% 73.53%
DII 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Sunil Healthcare Ltd. (this stock) 78 26.6 1.03 6.01%
Vaishali Pharma Limited 95 21.4 1.33 5.83%
Alpa Laboratories Ltd 109 52.0 0.59 8.38%
Mangalam Drug & Chem Ltd 45 — 0.51 -35.3%
Vivimed Labs Limited 43 — -0.2 —
Vivo Bio Tech Ltd. 35 — 0.37 -2.24%
Medi Caps Ltd. 33 — 0.27 -9.21%

Which Mutual Funds Hold Sunil Healthcare Ltd.?

Frequently Asked Questions about Sunil Healthcare Ltd.

Community Sentiment

What are other investors saying about Sunil Healthcare Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.